

(FILE 'REGISTRY' ENTERED AT 12:04:32 ON 22 NOV 2006)


FILE 'CAPLUS' ENTERED AT 12:08:03 ON 22 NOV 2006

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.79	185.14
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.25	-2.25


STN INTERNATIONAL LOGOFF AT 12:08:50 ON 22 NOV 2006

L5 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:1118713 CAPLUS Full-text
 TI Preparation of diazepanes as LFA-1 inhibitors
 IN Oberhauser, Berndt; Scholz, Dieter
 PA Novartis AG, Switz.; Novartis Pharma GmbH
 SO PCT Int. Appl., 60pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006111371	A1	20061026	WO 2006-EP3583	20060419
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	PRAI GB 2005-7918	A	20050419		
	GI				



I



I

AB The title compds. I [R1 = alkyl; R2 = (un)substituted alkyl, alkenyl, alkynyl; R3 = (un)substituted aryl], e.g. useful for treating disorders or diseases mediated by LFA-1 (Leukocyte Function-Associated Antigen One), were prepared General procedures for synthesis of compds. I are given, and 65 compds. of I were prepared II showed inhibition of adhesion of LFA-1 to ICAM-1 with an IC50 value of 0.09 μ M.


IT 913357-85-4P 913358-41-5P 913358-53-9P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of diazepanes as LFA-1 inhibitors)

RN 913357-85-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


CRN 913357-84-3
CMF C28 H31 Cl N4 O3

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 913358-41-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 913358-53-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



IT 913357-86-5P 913357-87-6P 913357-88-7P
913357-89-8P 913357-90-1P 913357-91-2P


913357-92-3P 913357-93-4P 913357-94-5P
 913357-96-7P 913357-98-9P 913357-99-0P
 913358-01-7P 913358-03-9P 913358-04-0P
 913358-05-1P 913358-07-3P 913358-09-5P
 913358-11-9P 913358-12-0P 913358-13-1P
 913358-15-3P 913358-17-5P 913358-18-6P
 913358-19-7P 913358-21-1P 913358-23-3P
 913358-24-4P 913358-25-5P 913358-26-6P
 913358-27-7P 913358-28-8P 913358-30-2P
 913358-31-3P 913358-32-4P 913358-33-5P
 913358-35-7P 913358-36-8P 913358-37-9P
 913358-38-0P 913358-39-1P 913358-40-4P
 913358-42-6P 913358-43-7P 913358-44-8P
 913358-45-9P 913358-46-0P 913358-47-1P
 913358-48-2P 913358-49-3P 913358-50-6P
 913358-51-7P 913358-52-8P 913358-54-0P
 913358-55-1P 913358-56-2P 913358-57-3P
 913358-58-4P 913358-59-5P 913358-60-8P
 913358-61-9P 913358-62-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses) (preparation of diazepanes as LFA-1 inhibitors)

RN 913357-86-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




● HCl

RN 913357-87-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




● HCl

RN 913357-88-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



● HCl

RN 913357-89-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



● HCl

RN 913357-90-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



● HCl

RN 913357-91-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



● HCl

RN 913357-92-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



● HCl


RN 913357-93-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 913357-94-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 913357-96-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 913357-95-6
CMF C29 H32 Cl N5 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 913357-98-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 913357-97-8
CMF C35 H42 Cl N5 O6


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913357-99-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 913358-01-7 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM . 1

CRN 913358-00-6

CMF C32 H36 C1 N5 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 913358-03-9 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 913358-02-8


CMF C32 H36 Cl N5 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 913358-04-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 913358-05-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 913358-07-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 913358-06-2
CMF C37 H45 Cl N6 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 913358-09-5 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 913358-08-4


CMF C33 H38 Cl N5 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 913358-11-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 913358-10-8
CMF C33 H38 Cl N5 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 913358-12-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 913358-13-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 913358-15-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 913358-14-2
CMF C33 H38 Cl N5 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 913358-17-5 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 913358-16-4

CMF C34 H40 Cl N5 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913358-18-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



● HCl

RN 913358-19-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




● HCl

RN 913358-21-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 913358-20-0
CMF C33 H39 Cl N6 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 913358-23-3 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 913358-22-2

CMF C33 H39 Cl N6 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913358-24-4 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 913358-25-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



● HCl

RN 913358-26-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



● HCl

RN 913358-27-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



● HCl

RN 913358-28-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




● HCl

RN 913358-30-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 913358-29-9
CMF C30 H34 Cl N5 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 913358-31-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



● HCl

RN 913358-32-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



● Cl⁻

RN 913358-33-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 913358-35-7 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 913358-34-6

CMF C31 H36 Cl N5 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913358-36-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 913358-37-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 913358-38-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 913358-39-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 913358-40-4 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 913358-42-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 913358-43-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 913358-44-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 913358-45-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 913358-46-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




● HCl

RN 913358-47-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 913358-48-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 913358-49-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 913358-50-6 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 913358-51-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 913358-52-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 913358-54-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

Double bond geometry as shown.




RN 913358-55-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 913358-56-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 913358-57-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



● HCl

RN 913358-58-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



● HCl

RN 913358-59-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



● HCl

RN 913358-60-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



● HCl

RN 913358-61-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



● HCl

RN 913358-62-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



● HCl


IT 913358-63-1 913358-64-2 913358-66-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of diazepanes as LFA-1 inhibitors)
RN 913358-63-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 913358-64-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 913358-66-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

App's

L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:633924 CAPLUS Full-text
DN 141:174198
TI Preparation of diazepanes as LFA inhibitors
IN Oberhauser, Berndt; Meingassner, Gottfried
PA Novartis Ag, Switz.; Novartis Pharma GmbH
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004065382	A1	20040805	WO 2004-EP514	20040122
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
	AU 2004205504	A1	20040805	AU 2004-205504	20040122
	CA 2509764	AA	20040805	CA 2004-2509764	20040122
	EP 1590342	A1	20051102	EP 2004-704212	20040122
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2004006884	A	20060103	BR 2004-6884	20040122
	CN 1735609	A	20060215	CN 2004-80002163	20040122
	JP 2006515335	T2	20060525	JP 2006-500007	20040122
	ZA 2005004672	A	20060222	ZA 2005-4672	20050608
	US 2006148780	A1	20060706	US 2005-541183	20050630
	NO 2005003911	A	20051024	NO 2005-3911	20050822
PRAI	GB 2003-1561	A	20030123		
	GB 2003-23976	A	20031013		
	WO 2004-EP514	W	20040122		
OS	MARPAT 141:174198				
GI					



I

AB The title compds. [I; R1 = alkyl; R2 = alkyl, arylalkyl, etc.; R3 = aryl], e.g. useful for treating disorders or diseases mediated by LFA-1/ICAM-1, LFA-1/ICAM-2, LFA-1/ICAM-3 or LFA-1/JAM-1 interactions, were prepared General procedures for synthesis of compds. I are given. 43 Compds. I were prepared The compound I [R1 = Me; R2 = 6-quinolinylmethyl; R3 = 3-Cl-4-FC6H3] was tested for inhibition of allergic contact dermatitis (ACD) in vivo in mice, and exhibited an inhibition of the inflammatory response by 40-50% at 0.01-10.0 mg/kg.


IT 733802-07-8P 733802-08-9P 733802-09-0P
733802-10-3P 733802-11-4P 733802-13-6P
733802-14-7P 733802-15-8P 733802-16-9P
733802-17-0P 733802-19-2P 733802-20-5P
733802-21-6P 733802-22-7P 733802-23-8P
733802-24-9P 733802-25-0P 733802-26-1P
733802-27-2P 733802-28-3P 733802-29-4P
733802-30-7P 733802-31-8P 733802-32-9P
733802-33-0P 733802-34-1P 733802-35-2P

733802-37-4P 733802-38-5P 733802-40-9P
 733802-41-0P 733802-42-1P 733802-44-3P
 733802-45-4P 733802-47-6P 733802-48-7P
 733802-49-8P 733802-50-1P 733802-51-2P
 733802-52-3P 733802-54-5P 733802-55-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of diazepam as LFA inhibitors)


RN 733802-07-8 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, 3-(3-fluorophenyl)hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo-4-(6-quinolinylacetyl)- (9CI) (CA INDEX NAME)




RN 733802-08-9 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo-4-(6-quinolinylacetyl)-3-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 733802-09-0 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, 3-(4-fluorophenyl)hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo-4-(6-quinolinylacetyl)- (9CI) (CA INDEX NAME)




RN 733802-10-3 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, 3-(2-fluorophenyl)hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo-4-(6-quinolinylacetyl)- (9CI) (CA INDEX NAME)



RN 733802-11-4 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, 3-(3-bromophenyl)hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo-4-(6-quinolinylacetyl)- (9CI) (CA INDEX NAME)




RN 733802-13-6 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, 3-[1,1'-biphenyl]-3-ylhexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo-4-(6-quinolinylacetyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 733802-12-5


CMF C42 H38 N4 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 733802-14-7 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, 3-(3-chlorophenyl)hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo-4-(6-quinolinylacetyl)- (9CI) (CA INDEX NAME)




RN 733802-15-8 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, 3-(3,5-dichlorophenyl)hexahydro-5-methyl-
α-(1-naphthalenylmethyl)-2-oxo-4-(6-quinolinylacetyl)- (9CI) (CA
INDEX NAME)




RN 733802-16-9 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, 3-[4-chloro-3-(trifluoromethyl)phenyl]hexahy-
dro-5-methyl-α-(1-naphthalenylmethyl)-2-oxo-4-(6-quinolinylacetyl)-
(9CI) (CA INDEX NAME)



RN 733802-17-0 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, 3-(3-chloro-4-fluorophenyl)hexahydro-5-
methyl-α-(1-naphthalenylmethyl)-2-oxo-4-(6-quinolinylacetyl)- (9CI)
(CA INDEX NAME)




RN 733802-19-2 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, hexahydro-5-methyl-α-(1-
naphthalenylmethyl)-2-oxo-4-(6-quinolinylacetyl)-3-[2-
(trifluoromethyl)phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 733802-18-1


CMF C37 H33 F3 N4 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 733802-20-5 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, 3-(3,4-difluorophenyl)hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo-4-(6-quinolinylacetyl)- (9CI) (CA INDEX NAME)




RN 733802-21-6 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, 3-(3-cyanophenyl)hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo-4-(6-quinolinylacetyl)- (9CI) (CA INDEX NAME)




RN 733802-22-7 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo-3-[3-(5-pyrimidinyl)phenyl]-4-(6-quinolinylacetyl)- (9CI) (CA INDEX NAME)




RN 733802-23-8 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo-4-(6-quinolinylacetyl)-3-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 733802-24-9 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, 4-(1,3-benzodioxol-5-ylacetyl)-3-(3-fluorophenyl)hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 733802-25-0 CAPLUS


CN 1H-1,4-Diazepine-1-acetamide, 4-(1,3-benzodioxol-5-ylacetyl)-3-(3-chlorophenyl)hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 733802-26-1 CAPLUS


CN 1H-1,4-Diazepine-1-acetamide, 4-(1,3-benzodioxol-5-ylacetyl)hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo-3-[3-(trifluoromethyl)phenyl]-

(9CI) (CA INDEX NAME)




RN 733802-27-2 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, 4-(1,3-benzodioxol-5-ylacetyl)-3-(3-chloro-4-fluorophenyl)hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 733802-28-3 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, 4-(1,3-benzodioxol-5-ylacetyl)-3-(3-cyanophenyl)hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 733802-29-4 CAPLUS


CN 1H-1,4-Diazepine-1-acetamide, 4-(1,3-benzodioxol-5-ylacetyl)hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo-3-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 733802-30-7 CAPLUS


CN 1H-1,4-Diazepine-1-acetamide, 3-(3-chlorophenyl)hexahydro-5-methyl- α -

(1-naphthalenylmethyl)-2-oxo-4-(phenylacetyl)- (9CI) (CA INDEX NAME)



RN 733802-31-8 CAPLUS


CN 1H-1,4-Diazepine-1-acetamide, 3-(3-fluorophenyl)hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo-4-[[3-(trifluoromethyl)phenyl]acetyl]- (9CI)
(CA INDEX NAME)




RN 733802-32-9 CAPLUS



CN 1H-1,4-Diazepine-1-acetamide, 3-[1,1'-biphenyl]-4-ylhexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo-4-[(2,3,6-trichlorophenyl)acetyl]- (9CI) (CA INDEX NAME)

PAGE 1-A







RN 733802-33-0 CAPLUS
 CN 1H-1,4-Diazepine-1-acetamide, 4-[(4-cyanophenyl)acetyl]-3-(3,4-difluorophenyl)hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo-
 (9CI) (CA INDEX NAME)



RN 733802-34-1 CAPLUS
 CN 1H-1,4-Diazepine-1-acetamide, 3-(3-chlorophenyl)-4-[(4-cyanophenyl)acetyl]hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo-
 (9CI) (CA INDEX NAME)




PAGE 2-A




RN 733802-35-2 CAPLUS
CN 1H-1,4-Diazepine-1-acetamide, 4-[(4-aminophenyl)acetyl]-3-(3-chlorophenyl)hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo-(9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 733802-37-4 CAPLUS
CN 1H-1,4-Diazepine-1-acetamide, 4-[(4-aminophenyl)acetyl]hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo-3-[3-(trifluoromethyl)phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 733802-36-3
CMF C34 H33 F3 N4 O3





CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 733802-38-5 CAPLUS
CN 1H-1,4-Diazepine-1-acetamide, 4-[[4-(dimethylamino)phenyl]acetyl]hexahydro-5-methyl-α-(1-naphthalenylmethyl)-2-oxo-3-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)






RN 733802-40-9 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, 4-[(3-aminophenyl)acetyl]-3-(3-chlorophenyl)hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 733802-39-6


CMF C33 H33 Cl N4 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 733802-41-0 CAPLUS

CN Butanoic acid, 4-[[4-[2-[4-[2-amino-1-(1-naphthalenylmethyl)-2-oxoethyl]hexahydro-7-methyl-3-oxo-2-[3-(trifluoromethyl)phenyl]-1H-1,4-diazepin-1-yl]-2-oxoethyl]phenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733802-42-1 CAPLUS
CN Butanoic acid, 4-[[[4-[2-[4-[2-amino-1-(1-naphthalenylmethyl)-2-oxoethyl]-2-(3-chlorophenyl)hexahydro-7-methyl-3-oxo-1H-1,4-diazepin-1-yl]-2-oxoethyl]phenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 733802-44-3 CAPLUS
CN 1H-1,4-Diazepine-1-acetamide, 4-[[[4-[(aminoacetyl)amino]phenyl]acetyl]-3-(3-chlorophenyl)hexahydro-5-methyl-α-(1-naphthalenylmethyl)-2-oxo-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 733802-43-2
CMF C35 H36 Cl N5 O4

PAGE 1-A




PAGE 2-A




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 733802-45-4 CAPLUS
CN 1H-1,4-Diazepine-1-acetamide, 4-[[3-[(aminoacetyl)amino]phenyl]acetyl]-3-(3-chlorophenyl)hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 733802-47-6 CAPLUS
CN 1H-1,4-Diazepine-1-acetamide, 4-[[4-[(3-amino-1-oxopropyl)amino]phenyl]acetyl]-3-(3-chlorophenyl)hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 733802-46-5
CMF C36 H38 Cl N5 O4

PAGE 1-A




PAGE 2-A




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 733802-48-7 CAPLUS
CN 1H-1,4-Diazepine-1-acetamide, 3-(3-chlorophenyl)hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo-4-[[4-[(1-oxo-2-propenyl)amino]phenyl]acetyl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733802-49-8 CAPLUS
CN 1H-1,4-Diazepine-1-acetamide, 3-(3-chlorophenyl)hexahydro-5-methyl-4-[[4-[[4-(4-morpholinyl)-1,4-dioxobutyl]amino]phenyl]acetyl]- α -(1-naphthalenylmethyl)-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733802-50-1 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, 3-(3-chlorophenyl)-4-[[4-[[1,4-dioxo-4-(1-piperazinyl)butyl]amino]phenyl]acetyl]hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo- (9CI) (CA INDEX NAME)


PAGE 1-A






RN 733802-51-2 CAPLUS


CN 1H-1,4-Diazepine-1-acetamide, 3-(3-chlorophenyl)hexahydro-4-[(2-methoxyphenyl)acetyl]-5-methyl- α -(1-naphthalenylmethyl)-2-oxo- (9CI)
(CA INDEX NAME)



RN 733802-52-3 CAPLUS



CN 1H-1,4-Diazepine-1-acetamide, 3-(3-chlorophenyl)hexahydro-4-[(4-methoxyphenyl)acetyl]-5-methyl- α -(1-naphthalenylmethyl)-2-oxo- (9CI)
(CA INDEX NAME)






RN 733802-54-5 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, 4-[(3-chloro-4-methoxyphenyl)acetyl]-3-(3-chlorophenyl)hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 733802-55-6 CAPLUS


CN 1H-1,4-Diazepine-1-acetamide, 4-acetyl-3-(3-chlorophenyl)hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2001:283944 CAPLUS Full-text
 DN 134:311434
 TI Preparation of naphthylalaninyldiazepinones and related compounds for treating disorders or diseases mediated by LFA-1/ICAM-1, -ICAM-2 or -ICAM-3 interactions.
 IN Albert, Rainer; Ehrhardt, Claus; Hommel, Ulrich; Kallen, Joerg; Meingassner, Josef Gottfried; Roche, Didier; Wattanasin, Sompong; Weitz-Schmidt, Gabriele; Welzenbach, Karl
 PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
 SO PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001027102	A1	20010419	WO 2000-EP10025	20001011
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6399599	B1	20020604	US 2000-686511	20001011
	EP 1220852	A1	20020710	EP 2000-969490	20001011
	EP 1220852	B1	20060118		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, IE, SI, LT, LV, FI, RO, MK, CY, AL, PT, SE				
	JP 2003511447	T2	20030325	JP 2001-530320	20001011
	AT 316084	E	20060215	AT 2000-969490	20001011
	PT 1220852	T	20060531	PT 2000-969490	20001011
	ES 2257328	T3	20060801	ES 2000-969490	20001011
PRAI	US 1999-266325P	P	19991013		
	US 1999-416815	A	19991013		
	EP 2000-969490	A	20001011		
	WO 2000-EP10025	W	20001011		
OS	MARPAT 134:311434				
GI					



AB Title compds. [I; n = 1-3; R1 = H, alkyl, aryl, aralkyl; Y = alkylene, alkenylene, CONH, CO2, etc.; R2 = (substituted) aryl, heteroaryl; R3 = amino acid side chain; R4 = (substituted) biphenyl, PhCH2, hydroxybenzyl, β -naphthylmethyl, tetrahydro- β -naphthylmethyl, indolylmethyl; X = cyano, amino, OH, alkoxy, etc.], were prepared Thus, (S)-2-[(3S,5R)-3-isobutyl-5-methyl-2-oxo-1,4-diazepan-1-yl]-3-(naphthalen-2-yl)propionamide, 6-quinolylacetic acid, (Me2CH)2NEt, and EADC were stirred 16 h in CH2Cl2 to give (S)-2-[(3S,5R)-3-isobutyl-5-methyl-2-oxo-4-(quinolin-6-ylacetyl)-1,4-diazepan-1-

yl]-3-(naphthalen-2-yl)propionamide. The latter inhibited adhesion of LFA-1 to ICAM-1 with IC50 = 0.44 μ M.

IT 334941-36-5P 334941-49-0P 334941-54-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of naphthylalaninyldiazepinones and related compds. for treating disorders or diseases mediated by LFA-1/ICAM-1, -ICAM-2 or -ICAM-3 interactions)

RN 334941-36-5 CAPLUS


CN 1H-1,4-Diazepine-1-acetamide, hexahydro-5-methyl- α -(2-naphthalenylmethyl)-2-oxo-3-phenyl-4-(6-quinolinylacetyl)-, (α R,3S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 334941-49-0 CAPLUS


CN 1H-1,4-Diazepine-1-acetamide, hexahydro-5-methyl-4-(2-naphthalenylacetyl)- α -(1-naphthalenylmethyl)-2-oxo-3-phenyl- (9CI) (CA INDEX NAME)



RN 334941-54-7 CAPLUS

CN 1H-1,4-Diazepine-1-acetamide, 4-[(3,4-dichlorophenyl)acetyl]hexahydro-5-methyl- α -(1-naphthalenylmethyl)-2-oxo-3-phenyl- (9CI) (CA INDEX NAME)





RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT